Published in Infect Immun on April 01, 1995
What makes Cryptococcus neoformans a pathogen? Emerg Infect Dis (1998) 2.18
The capsule of the fungal pathogen Cryptococcus neoformans. Adv Appl Microbiol (2009) 1.97
Macrophages in resistance to candidiasis. Microbiol Mol Biol Rev (1997) 1.74
Extracellular vesicles from Cryptococcus neoformans modulate macrophage functions. Infect Immun (2010) 1.40
Nitrosative and oxidative stress responses in fungal pathogenicity. Curr Opin Microbiol (2009) 1.28
Mechanisms of resistance to oxidative and nitrosative stress: implications for fungal survival in mammalian hosts. Eukaryot Cell (2004) 1.26
The Cryptococcus neoformans catalase gene family and its role in antioxidant defense. Eukaryot Cell (2006) 1.24
Expression of inducible nitric oxide synthase in rat pulmonary Cryptococcus neoformans granulomas. Am J Pathol (1996) 1.07
Evidence for branching in cryptococcal capsular polysaccharides and consequences on its biological activity. Mol Microbiol (2011) 1.01
Structure and biological activities of acapsular Cryptococcus neoformans 602 complemented with the CAP64 gene. Infect Immun (1997) 0.97
Capsular Material of Cryptococcus neoformans: Virulence and Much More. Mycopathologia (2012) 0.90
Classical versus alternative macrophage activation: the Ying and the Yang in host defense against pulmonary fungal infections. Mucosal Immunol (2014) 0.90
Cryptococcus neoformans phosphoinositide-dependent kinase 1 (PDK1) ortholog is required for stress tolerance and survival in murine phagocytes. Eukaryot Cell (2012) 0.86
Blastomyces dermatitidis yeast cells inhibit nitric oxide production by alveolar macrophage inducible nitric oxide synthase. Infect Immun (2011) 0.83
Cryptococcus and Phagocytes: Complex Interactions that Influence Disease Outcome. Front Microbiol (2016) 0.79
Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol (1988) 14.21
Macrophage oxidation of L-arginine to nitrite and nitrate: nitric oxide is an intermediate. Biochemistry (1988) 10.17
Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med (1985) 8.18
Mammalian nitrate biosynthesis: mouse macrophages produce nitrite and nitrate in response to Escherichia coli lipopolysaccharide. Proc Natl Acad Sci U S A (1985) 7.36
Nonencapsulated Variant of Cryptococcus neoformans I. Virulence Studies and Characterization of Soluble Polysaccharide. Infect Immun (1971) 5.45
Cryptococcus neoformans. I. Nonencapsulated mutants. J Bacteriol (1967) 5.15
Induction of nitrite/nitrate synthesis in murine macrophages by BCG infection, lymphokines, or interferon-gamma. J Immunol (1987) 5.00
Microbiostatic effect of murine-activated macrophages for Toxoplasma gondii. Role for synthesis of inorganic nitrogen oxides from L-arginine. J Immunol (1990) 4.62
Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism. J Immunol (1990) 4.36
Interferon-gamma and tumor necrosis factor induce the L-arginine-dependent cytotoxic effector mechanism in murine macrophages. Eur J Immunol (1988) 4.04
Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide. J Clin Invest (1985) 3.98
The capsule of cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages. J Immunol (1982) 3.92
Leishmania major amastigotes initiate the L-arginine-dependent killing mechanism in IFN-gamma-stimulated macrophages by induction of tumor necrosis factor-alpha. J Immunol (1990) 3.79
Specific amino acid (L-arginine) requirement for the microbiostatic activity of murine macrophages. J Clin Invest (1988) 3.69
Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. J Immunol (1990) 3.56
Macrophage deactivating factor and transforming growth factors-beta 1 -beta 2 and -beta 3 inhibit induction of macrophage nitrogen oxide synthesis by IFN-gamma. J Immunol (1990) 3.55
Activation of macrophages for destruction of Francisella tularensis: identification of cytokines, effector cells, and effector molecules. Infect Immun (1992) 3.09
Macrophage cytotoxicity against schistosomula of Schistosoma mansoni involves arginine-dependent production of reactive nitrogen intermediates. J Immunol (1989) 3.09
Genetic and phenotypic characterization of capsule mutants of Cryptococcus neoformans. J Bacteriol (1982) 2.96
Metabolic fate of L-arginine in relation to microbiostatic capability of murine macrophages. J Clin Invest (1990) 2.91
IL-10 synergizes with IL-4 and transforming growth factor-beta to inhibit macrophage cytotoxic activity. J Immunol (1992) 2.78
A simple, non-chromatographic procedure to purify immunoglobulins from serum and ascites fluid. J Immunol Methods (1987) 2.74
Release of nitric oxide during the T cell-independent pathway of macrophage activation. Its role in resistance to Listeria monocytogenes. J Immunol (1993) 2.73
Synthesis of nitrite and nitrate in murine macrophage cell lines. Cancer Res (1987) 2.69
Regulation of Trypanosoma cruzi infections in vitro and in vivo by transforming growth factor beta (TGF-beta). J Exp Med (1991) 2.68
Urinary nitrate excretion in relation to murine macrophage activation. Influence of dietary L-arginine and oral NG-monomethyl-L-arginine. J Immunol (1991) 2.60
Release of tumor necrosis factor-alpha from macrophages. Enhancement and suppression are dose-dependently regulated by prostaglandin E2 and cyclic nucleotides. J Immunol (1988) 2.58
Regulation of cell-mediated immunity in cryptococcosis. I. Induction of specific afferent T suppressor cells by cryptococcal antigen. J Immunol (1982) 2.36
Inhibition of Cryptococcus neoformans replication by nitrogen oxides supports the role of these molecules as effectors of macrophage-mediated cytostasis. Infect Immun (1991) 2.23
Macrophage activation for tumor cytotoxicity: development of macrophage cytotoxic activity requires completion of a sequence of short-lived intermediary reactions. J Immunol (1978) 2.12
Macrophage-mediated fungistasis in vitro: requirements for intracellular and extracellular cytotoxicity. J Immunol (1986) 2.06
Interleukin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of Candida albicans. Eur J Immunol (1993) 2.05
Differential stimulation of murine resident peritoneal cells by selectively opsonized encapsulated and acapsular Cryptococcus neoformans. Infect Immun (1988) 2.05
Nitric oxide produced during murine listeriosis is protective. Infect Immun (1994) 1.93
Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans. Infect Immun (1991) 1.90
Human alveolar and peritoneal macrophages mediate fungistasis independently of L-arginine oxidation to nitrite or nitrate. Am Rev Respir Dis (1990) 1.90
Role of inorganic nitrogen oxides and tumor necrosis factor alpha in killing Leishmania donovani amastigotes in gamma interferon-lipopolysaccharide-activated macrophages from Lshs and Lshr congenic mouse strains. Infect Immun (1991) 1.84
Mammalian nitrate biosynthesis: incorporation of 15NH3 into nitrate is enhanced by endotoxin treatment. Proc Natl Acad Sci U S A (1983) 1.83
Phagocytosis of Cryptococcus neoformans by alveolar macrophages. Infect Immun (1975) 1.83
Differential inhibition of IL-1 and TNF-alpha mRNA expression by agents which block second messenger pathways in murine macrophages. J Immunol (1988) 1.55
Macrophage activation for tumor cytotoxicity: characterization of priming and trigger signals during lymphokine activation. J Immunol (1981) 1.40
Macrophage cytostatic effect on Trypanosoma musculi involves an L-arginine-dependent mechanism. J Immunol (1991) 1.27
Endotoxin tolerance is associated with reduced secretion of tumor necrosis factor. Arch Surg (1989) 1.26
Recombinant murine gamma interferon stimulates macrophages of the RAW cell line to inhibit intracellular growth of Histoplasma capsulatum. Infect Immun (1994) 1.24
Recombinant C5a enhances interleukin 1 and tumor necrosis factor release by lipopolysaccharide-stimulated monocytes and macrophages. Eur J Immunol (1990) 1.23
Production of tumor necrosis factors alpha and beta by human mononuclear leukocytes stimulated with mitogens, bacteria, and malarial parasites. Infect Immun (1990) 1.14
Macrophage-mediated fungistasis: requirement for a macromolecular component in serum. J Immunol (1986) 1.12
Modified determination of citrulline. Anal Biochem (1968) 1.07
A specific sequence of stimulation is required to induce synthesis of the antimicrobial molecule nitric oxide by mouse macrophages. Infect Immun (1992) 1.06
Membrane potential modulates release of tumor necrosis factor in lipopolysaccharide-stimulated mouse macrophages. Mol Biol Cell (1992) 0.96
Phorbol esters and calcium ionophore can prime murine peritoneal macrophages for tumor cell destruction. J Immunol (1986) 0.93
Opsonic activity of cerebrospinal fluid in experimental cryptococcal meningitis. Infect Immun (1990) 0.91
Perinatal depression: prevalence, screening accuracy, and screening outcomes. Evid Rep Technol Assess (Summ) (2005) 6.10
Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide. J Clin Invest (1985) 3.98
Trichomonas vaginalis as a cause of urethritis in Malawian men. Sex Transm Dis (1999) 3.12
Nitric oxide in Tanzanian children with malaria: inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expression. J Exp Med (1996) 2.75
Sites of inhibition of mitochondrial electron transport in macrophage-injured neoplastic cells. J Cell Biol (1982) 2.54
Inhibition of Cryptococcus neoformans replication by nitrogen oxides supports the role of these molecules as effectors of macrophage-mediated cytostasis. Infect Immun (1991) 2.23
Reassessing the role of epidemiology in public health. Am J Public Health (1999) 2.20
Sex differences in nevirapine rash. Clin Infect Dis (2000) 2.09
HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. AIDS (2001) 2.08
Macrophage-mediated fungistasis in vitro: requirements for intracellular and extracellular cytotoxicity. J Immunol (1986) 2.06
Nitric oxide produced during murine listeriosis is protective. Infect Immun (1994) 1.93
Human alveolar and peritoneal macrophages mediate fungistasis independently of L-arginine oxidation to nitrite or nitrate. Am Rev Respir Dis (1990) 1.90
Effect of in vivo inhibition of nitric oxide production in murine leishmaniasis. J Immunol (1993) 1.88
Effects of antifungal agents and gamma interferon on macrophage cytotoxicity for fungi and tumor cells. J Infect Dis (1987) 1.85
Injury of neoplastic cells by murine macrophages leads to inhibition of mitochondrial respiration. J Clin Invest (1980) 1.82
Spasticity outcome measures in spinal cord injury: psychometric properties and clinical utility. Spinal Cord (2007) 1.67
Spatial analysis and mapping of sexually transmitted diseases to optimise intervention and prevention strategies. Sex Transm Infect (2004) 1.66
Neutralization of gamma interferon and tumor necrosis factor alpha blocks in vivo synthesis of nitrogen oxides from L-arginine and protection against Francisella tularensis infection in Mycobacterium bovis BCG-treated mice. Infect Immun (1993) 1.65
Mitochondrial iron loss from leukemia cells injured by macrophages. A possible mechanism for electron transport chain defects. J Immunol (1988) 1.41
Can we do better than discrepant analysis for new diagnostic test evaluation? Clin Infect Dis (1998) 1.37
Migration inhibitory factor and type II interferon in the circulation of mice sensitized with mycobacterial components. J Immunol (1975) 1.33
Delayed hypersensitivity and granulomatous response after immunization with protein antigens associated with a mycobacterial glycolipid and oil droplets. J Immunol (1976) 1.31
Quality of life instruments and definitions in individuals with spinal cord injury: a systematic review. Spinal Cord (2009) 1.27
Growth inhibition of Cryptococcus neoformans by human alveolar macrophages. Am Rev Respir Dis (1987) 1.20
Cerebrospinal fluid macrophage response to experimental cryptococcal meningitis: relationship between in vivo and in vitro measurements of cytotoxicity. Infect Immun (1988) 1.19
Tumor regression caused by endotoxins and mycobacterial fractions. J Natl Cancer Inst (1975) 1.17
Concordance of chlamydia trachomatis infections within sexual partnerships. Sex Transm Infect (2007) 1.16
Smoke inhalation in firemen. Thorax (1980) 1.16
Measuring nitric oxide production in human clinical studies. Methods Enzymol (1999) 1.13
Macrophage-mediated fungistasis: requirement for a macromolecular component in serum. J Immunol (1986) 1.12
Trends of gonorrhea and chlamydial infection during 1985-1996 among active-duty soldiers at a United States Army installation. Clin Infect Dis (2000) 1.12
Adaptations to a high-fat diet that increase exercise endurance in male rats. J Appl Physiol Respir Environ Exerc Physiol (1984) 1.09
A promoter polymorphism in the gene encoding interleukin-12 p40 (IL12B) is associated with mortality from cerebral malaria and with reduced nitric oxide production. Genes Immun (2002) 1.07
Biopersistence of synthetic vitreous fibers and amosite asbestos in the rat lung following inhalation. Toxicol Appl Pharmacol (1998) 1.06
Infectious arthritis due to Propionibacterium acnes in a prosthetic joint. Clin Infect Dis (1994) 1.06
LCR testing for gonorrhoea and chlamydia in population surveys and other screenings of low prevalence populations: coping with decreased positive predictive value. Sex Transm Infect (2003) 1.05
A review of instruments assessing participation in persons with spinal cord injury. Spinal Cord (2009) 1.05
Evaluation of the BOD POD for estimating percentage body fat in a heterogeneous group of adult humans. Eur J Appl Physiol (2001) 1.04
A systematic review of depression and anxiety measures used with individuals with spinal cord injury. Spinal Cord (2009) 1.03
Detectable HIV-1 RNA at levels below quantifiable limits by amplicor HIV-1 monitor is associated with virologic relapse on antiretroviral therapy. AIDS (1999) 1.01
Alveolar proteinosis as a consequence of immunosuppression. A hypothesis based on clinical and pathologic observations. Hum Pathol (1980) 1.01
Tuberculin reactivity in bacille Calmette-Guérin vaccinated populations: a compilation of international data. Int J Tuberc Lung Dis (2006) 1.01
Mechanisms of oxygen effects on exercise in patients with chronic obstructive pulmonary disease. Chest (1982) 1.01
Respiratory failure in cancer patients. JAMA (1979) 1.00
Clinical correlates of fatigue in spinal cord injury. Spinal Cord (2007) 1.00
Induction of resistance to tuberculosis in mice with defined components of mycobacteria and with some unrelated materials. Immunology (1982) 0.98
An evidence-based review of aging of the body systems following spinal cord injury. Spinal Cord (2010) 0.98
Nitric oxide synthase type 2 promoter polymorphisms, nitric oxide production, and disease severity in Tanzanian children with malaria. J Infect Dis (1999) 0.98
Isoelectric point of albumin: effect on renal handling of albumin. Kidney Int (1979) 0.97
Structure and biological activities of acapsular Cryptococcus neoformans 602 complemented with the CAP64 gene. Infect Immun (1997) 0.97
Recruitment of HIV/AIDS treatment-naïve patients to clinical trials in the highly active antiretroviral therapy era: influence of gender, sexual orientation and race. HIV Med (2010) 0.96
Are all recently detoxified alcoholics depressed? Am J Psychiatry (1979) 0.95
Nitric oxide, malaria, and anemia: inverse relationship between nitric oxide production and hemoglobin concentration in asymptomatic, malaria-exposed children. Am J Trop Med Hyg (1999) 0.95
The relationship between and predictors of quality of life after spinal cord injury at 3 and 15 months after discharge. Spinal Cord (2009) 0.94
Experimental pulmonary edema following re-expansion of pneumothorax. Am Rev Respir Dis (1973) 0.94
Cutaneous granulomatous response to BCG cell walls with reference to cancer immunotherapy. Infect Immun (1976) 0.94
Noncardiogenic pulmonary edema during vivax malaria. Clin Infect Dis (1999) 0.93
Enlarged pulmonary arteriovenous vessels in COPD. Another possible mechanism of hypoxemia. Chest (1984) 0.93
Medication use is associated with fatigue in a sample of community-living individuals who have a spinal cord injury: a chart review. Spinal Cord (2009) 0.92
Bartonella henselae: etiology of pulmonary nodules in a patient with depressed cell-mediated immunity. Clin Infect Dis (1995) 0.92
Opsonic activity of cerebrospinal fluid in experimental cryptococcal meningitis. Infect Immun (1990) 0.91
Clinical application of measurement of angiotensin-converting enzyme level. JAMA (1979) 0.91
Effects of age and parasitemia on nitric oxide production/leukocyte nitric oxide synthase type 2 expression in asymptomatic, malaria-exposed children. Am J Trop Med Hyg (1999) 0.90
Syndromic treatment of gonococcal and chlamydial infections in women seeking primary care for the genital discharge syndrome: decision-making. Bull World Health Organ (2001) 0.90
Pulmonary edema associated with propoxyphene intoxication. JAMA (1971) 0.90
Decreased angiotensin-converting enzyme in the adult respiratory distress syndrome. Am J Clin Pathol (1978) 0.90
Selection for expression of the gonococcal hemoglobin receptor during menses. J Infect Dis (2001) 0.89
Growth patterns reflect response to antiretroviral therapy in HIV-positive infants: potential utility in resource-poor settings. AIDS Patient Care STDS (2004) 0.89
Effect of nebulized lidocaine on reactive airways. Am Rev Respir Dis (1975) 0.88
Rational testing of the HIV-exposed infant. Pediatrics (2001) 0.88
Classification and measurement of pain in the spinal cord-injured population. Spinal Cord (2007) 0.87
Postoperative lobar torsion and gangrene. Thorax (1977) 0.87
Human immunodeficiency virus (HIV)-infected human blood monocytes and peritoneal macrophages have reduced anticryptococcal activity whereas HIV-infected alveolar macrophages retain normal activity. J Infect Dis (1994) 0.87
Use of sexually transmitted disease risk assessment algorithms for selection of intrauterine device candidates. Contraception (1999) 0.87
Effects of extracorporeal circulation upon behavior, personality, and brain function. II. Hemodynamic, metabolic, and psychometric correlations. Ann Surg (1971) 0.87
Evaluation of electrosurgical interference to low-power spread-spectrum local area net transceivers. J Clin Monit (1997) 0.87
Immunotherapy with nonviable microbial components. Ann N Y Acad Sci (1976) 0.86
Sexually transmitted diseases and human immunodeficiency virus infection: cause, effect, or both? Int J Infect Dis (1999) 0.86
Airway response to inhaled histamine in asymptomatic long-term marijuana smokers. J Allergy Clin Immunol (1981) 0.86
Clinical utility of measuring white blood cells on vaginal wet mount and endocervical gram stain for the prediction of chlamydial and gonococcal infections. Sex Transm Dis (2000) 0.85
Efficacy of immune therapy in early experimental Naegleria fowleri meningitis. Infect Immun (1987) 0.85
Fatigue and spinal cord injury: a qualitative analysis. Spinal Cord (2008) 0.85
A review of scales for assessing the risk of developing a pressure ulcer in individuals with SCI. Spinal Cord (2007) 0.85
A double-blind comparison of the efficacy and safety of lorazepam and diazepam in the treatment of the acute alcohol withdrawal syndrome. Clin Ther (1984) 0.85
Discharges AMA and AWOL: a new "revolving door syndrome". Psychiatr J Univ Ott (1988) 0.85
Nitrate levels in malaria. Trans R Soc Trop Med Hyg (1997) 0.84
Lymphocytotoxic antibodies in patients with inflammatory bowel disease and their spouses--evidence for a transmissible agent. Clin Exp Immunol (1977) 0.84
Novel Salmonella enterica serovar Typhimurium protein that is indispensable for virulence and intracellular replication. Infect Immun (2001) 0.84
Adiposity does not hinder the fitness response to exercise training in obese women. J Sports Med Phys Fitness (2000) 0.84
Body fat and exercise endurance in trained rats adapted to a high-fat and/or high-carbohydrate diet. J Appl Physiol (1985) (1996) 0.83
Dimenhydrinate (Dramamine) abuse: hallucinogenic experiences with a proprietary antihistamine. Am J Psychiatry (1972) 0.83
Monitoring STI prevalence using telephone surveys and mailed urine specimens: a pilot test. Sex Transm Infect (2005) 0.83
Effect of dietary fat on food intake, growth and body composition in rats. Growth (1984) 0.83
Monitoring behavioral changes in diabetes care with the diabetes self-management record. Diabetes Educ (1995) 0.83
Normative data for strength and flexibility of women throughout life. Eur J Appl Physiol Occup Physiol (1998) 0.82
Physiological responses to weight-loss intervention in inactive obese African-American and Caucasian women. J Sports Med Phys Fitness (2002) 0.82
The use of psychological test data to predict open-heart surgery outcome: a prospective study. Psychosom Med (1975) 0.81
Pulmonary function tests and bronchodilator responsiveness. J Asthma Res (1980) 0.81
Increased prevalence of advanced tuberculosis in rural low tuberculosis caseload counties in North Carolina. Int J Tuberc Lung Dis (2011) 0.81